Chest
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Indacaterol is an ultra-long-acting beta-adrenoceptor agonist which needs to be taken once a day, licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler. A year-long, placebo-controlled trial published in July 2010 suggests indacaterol may be significantly more effective than twice-daily formoterol in improving FEV1. There were some reductions in the need for rescue medication, but these were not significantly different; nor was there any difference in the rate of exacerbation between the 2 active treatments. We looked at our data regarding the use of Indacaterol in a tertiary care set up. This is a real life experience looking at how Indacaterol influences clinical (MRC dyspnoea scale) and physiological (Spirometry) parameters and exacerbation episodes. ⋯ The following authors have nothing to disclose: Raja Dhar, Sanjit Ray ChaudhuriNo Product/Research Disclosure Information.
-
TransplantationSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: In order to identify the characteristics of late-onset non-infectious pulmonary complications (LONIPCs) in children who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), we retrospectively evaluated the incidence, characteristics, and outcomes of LONIPCs in these patients. ⋯ The following authors have nothing to disclose: Jong-seo Yoon, Hwan Soo Kim, Jae Wook Lee, Yoon Hong Chun, Nack Gyun Chung, Hyun Hee Kim, Bin Cho, Hack Ki Kim, Joon Sung LeeNo Product/Research Disclosure Information.
-
Surgery Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Amiodarone induced thyrotoxicosis (AIT) is a serious complication of amiodarone treatment. After failure of medical treatment, total thyroidectomy allows to stop hyperthyroidism and restart the antiarrhythmic. ⋯ The following authors have nothing to disclose: Nuno Ferreira, Alejandro Arbelaez, Anna Gonzalez, Marius RocaNo Product/Research Disclosure Information.
-
Surgery Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Aortic arch abnormalities are rare, but right-retroesophageal-subclavian-artery is the most common of them. It is usually asymptomatic. Dysphagia lusoria and fistulas, associated with hematemesis have been reported, with a very high mortality rate. There is no standard therapeutic approach for them. ⋯ The following authors have nothing to disclose: José González García, Sebastian Peñafiel, Eugenia Libreros Niño, Diana Baquero VelandiaNo Product/Research Disclosure Information.
-
Telemedicine PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To describe the clinical trial protocol that aims to evaluate the effectiveness of telenursing on lung function in patients with heart failure (HF). ⋯ The following authors have nothing to disclose: Carolina Santos, Bárbara Sueli Moreira, Loyane Alves, Fernanda Mussi, Carolina Souza-MachadoNo Product/Research Disclosure Information.